Safety of Cyclophosphamide Therapy in Autoimmune Rheumatic Diseases
Cyclophosphamide (CYC) is one of the most potent antineoplastic and immunosuppressant agents. It is used as a drug of choice in many organ-threatening manifestations of systemic autoimmune rheumatic diseases (AIRDs) such as lupus nephritis, antineutrophil cytoplasmic antibody-associated vasculitis,...
Saved in:
Main Authors: | Ramaswamy Subramanian, Himanshu Pathak, Vinod Ravindran |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-01-01
|
Series: | Indian Journal of Rheumatology |
Subjects: | |
Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=2;spage=127;epage=135;aulast=Subramanian |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcome of therapy in biopsy proven lupus nephritis with cyclophosphamide or mycophenolate: Registry data from a South Indian tertiary care center
by: Keerthi Talari, et al.
Published: (2017-01-01) -
Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis
by: Božić-Majstorović Ljubinka, et al.
Published: (2024-01-01) -
Multidrug-resistant primary cutaneous tuberculosis: A rare cause of chronic nonhealing leg ulcer in systemic lupus erythematosus
by: Pawan Goel, et al.
Published: (2019-01-01) -
Interleukin-32 positive immune and resident cells in kidney samples from lupus patients: a pilot study
by: Simona Truglia, et al.
Published: (2025-01-01) -
Is renal biopsy always necessary to start immunosuppressive therapy in lupus nephritis?
by: Vasudevan Chelliah, et al.
Published: (2017-01-01)